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Burkholderia cepacia complex (Bcc) bacteria can adapt to the lung environment of
cystic fibrosis (CF) patients resulting in the emergence of a very difficult to eradicate
heterogeneous population leading to chronic infections associated with rapid lung
function loss and increased mortality. Among the important phenotypic modifications
is the variation of the lipopolysaccharide (LPS) structure at level of the O-antigen (OAg)
presence, influencing adherence, colonization and the ability to evade the host defense
mechanisms. The present study was performed to understand whether the loss of
OAg expression during CF infection can be considered a general phenomenon in
different Bcc species favoring its chronicity. In fact, it is still not clear why different Bcc
species/strains differ in their ability to persist in the CF lung and pathogenic potential. The
systematic two-decade-retrospective-longitudinal-screening conducted covered 357
isolates retrieved from 19 chronically infected patients receiving care at a central hospital
in Lisbon. The study involved 21 Bcc strains of six/seven Bcc species/lineages, frequently
or rarely isolated from CF patients worldwide. Different strains/clonal variants obtained
during infection gave rise to characteristic OAg-banding patterns. The twomost prevalent
and feared species, B. cenocepacia and B. multivorans, showed a tendency to lose the
OAg along chronic infection. B. cenocepacia recA lineage IIIA strains known to lead to
particularly destructive infections exhibit the most frequent OAg loss, compared with
lineage IIIB. The switch frequency increased with the duration of infection and the level
of lung function deterioration. For the first time, it is shown that the rarely found B.
cepacia and B. contaminans, whose representation in the cohort of patients examined
is abnormally high, keep the OAg even during 10- or 15-year infections. Data from
co-infections with different Bcc species reinforced these conclusions. Concerning the
two other rarely found species examined, B. stabilis exhibited a stable OAg expression
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phenotype over the infection period while for the single clone of the more distantly
related B. dolosa species, the OAg-chain was absent from the beginning of the 5.5-year
infection until the patient dead. This work reinforces the relevance attributed to the
OAg-expression switch suggesting marked differences in the various Bcc species.
Keywords: Burkholderia cepacia complex species, cystic fibrosis, chronic pulmonary infections,
lipopolysaccharide O-antigen, within-host clonal variation
INTRODUCTION
Chronic respiratory infections involving opportunistic pathogens
remain the leading cause of premature death of cystic fibrosis
(CF) patients (Cullen andMcClean, 2015), in particular the long-
term infections caused by Pseudomonas aeruginosa and bacteria
of the Burkholderia cepacia complex (Bcc). The Bcc is a group
of more than 20 closely-related species (Depoorter et al., 2016)
particularly feared by CF patients due to their very difficult
eradication, inter-patient transmission, and related increased
morbidity and decreased life expectancy (Mahenthiralingam
et al., 2005; Drevinek and Mahenthiralingam, 2010; Kenna
et al., 2017). The majority of CF patients who acquire Bcc
develops a chronic infection while a minority may clear
the infection spontaneously (Mahenthiralingam et al., 2005).
Pulmonary colonization with Bcc can cause an accelerated
decline in lung function and the “cepacia syndrome” that is
characterized by an uncontrolled deterioration with septicaemia
and necrotizing pneumonia that usually results in early death
(Mahenthiralingam et al., 2005). Inside the CF lung, Bcc bacteria
face stressful and changing environmental conditions as a
consequence of host immune defenses, inflammatory responses,
antimicrobials and reactive oxygen species (ROS), fluctuating
levels of nutrients, oxygen deprivation, high osmolarity, low
pH, biofilm growth, and the presence of other co-infecting
microbes (Hogardt and Heesemann, 2010; Döring et al., 2011;
Cullen and McClean, 2015). Consequently, during long-term
infection, the initial Bcc strain-population accumulates genetic
alterations leading to genotypic and phenotypic diversification
forming a heterogeneous bacterial community very difficult to
eradicate therapeutically (Lieberman et al., 2011, 2014; Madeira
et al., 2011, 2013; Silva et al., 2011, 2016; Moreira et al.,
2014; Nunvar et al., 2017). Such within-patient emergence of
multiple clonal variants was first described for themore prevalent
CF pathogen Pseudomonas aeruginosa (Markussen et al., 2014;
Winstanley et al., 2016) and proposed to provide a pool
of mutations affecting virulence and antimicrobial resistance
(Lorè et al., 2012; Marvig et al., 2013; Faure et al., 2018).
Several studies have shown that, during chronic infection,
alterations in the lipopolysaccharide (LPS) molecule, a complex
glycolipid covering the cell surface and shielding Gram-negative
bacteria from adverse host environments, may occur (Pier, 2007;
Maldonado et al., 2016; Faure et al., 2018). The LPS is one of
Abbreviations: Bcc, Burkholderia cepacia complex; CF, cystic fibrosis; HSM,
Hospital de Santa Maria, Centro Hospitalar Lisboa Norte; LPS, lipopolysaccharide;
OAg, O-antigen; RAPD, random amplified polymorphism DNA; MLST,
multilocus sequence typing; ST, MLST sequence type.
the most important components of pathogenic Gram-negative
bacteria cellular envelope being considered a major virulence
factor and contributing to adhesion, immune defenses evasion,
host colonization and adaptation to the infection niche (Vinion-
Dubiel and Goldberg, 2003; Pier, 2007; Maldonado et al., 2016).
The LPS structure is composed by three constituents: a highly
acylated lipid A, also known as endotoxin, covalently linked
to the central core oligosaccharide, and the O-antigen (OAg),
composed by repeating polysaccharide units of variable length
(Vinion-Dubiel and Goldberg, 2003). Most of the heterogeneity
in LPS molecules is found in the OAg polysaccharide and lipid-
A components (Pier, 2007; Maldonado et al., 2016; Faure et al.,
2018). The OAg component of the LPS is essential in several
pathogens for motility (swarming and twitching) (Toguchi et al.,
2000; Berry et al., 2009; Bowden et al., 2013), protection against
oxidative stress (Berry et al., 2009) and evasion from host
immune defenses (Murray et al., 2003; Saldias et al., 2009;
Kotrange et al., 2011; Kintz et al., 2017). LPS OAg is believed
to be an immunodominant molecule that can modulate host-
pathogen interaction (Ranf, 2016) and proposed to be under
selective pressure in Gram-negative bacteria (King et al., 2009;
Maldonado et al., 2016; Kintz et al., 2017). Longitudinal studies
of P. aeruginosa isolates from CF patients with chronic lung
infections revealed the conversion from smooth (in the early
isolates) to rough LPS with short or no OAg side chain at the
late-stage of infections rendering the bacteria non-typable and
less immunogenic (King et al., 2009; Maldonado et al., 2016;
Demirdjian et al., 2017). In Bcc bacteria, a few recent reports
also described the variation of the presence and/or modification
of the OAg during persistent infection of the CF lung and on
how this alteration may affect Bcc pathogenicity (Lieberman
et al., 2011; Maldonado et al., 2016; Silva et al., 2016; Hassan
et al., 2017). An extensive study on an epidemic outbreak of
Burkholderia dolosa during 16 years, involving 14 CF patients
and 112 isolates, has shown that several late isolates produce
an LPS exhibiting the OAg that was absent in the LPS of the
ancestral strain; this fact was related with the appearance of
two different mutations in the glycosyltransferase encoding gene
wbaD (Lieberman et al., 2011). The genome analysis of clones
and metagenomes of evolved B. cenocepacia biofilms, after more
than one thousand generations, unveiled a mutation in the
gene manC – a gene involved in mannose metabolism located
within the LPS biosynthesis gene cluster-resulting in the loss
of the LPS OAg (Traverse et al., 2013). Remarkably, mutations
in the same manC gene were previously found to disrupt OAg
biosynthesis in late B. cenocepacia (Saldias et al., 2009) or early B.
dolosa (Lieberman et al., 2011) isolates retrieved during chronic
infection. A comparative genomic analysis focused on sequential
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B. multivorans isolates obtained over 20 years of CF chronic
infection showed that late isolates accumulate three different
mutations in a locus homologous to thewbi gene cluster, involved
in LPS OAg biosynthesis, leading to OAg loss (Silva et al., 2016).
Another recent study involving eleven serial clonal variants of B.
cenocepacia recA lineage IIIA obtained from a CF patient over
a 3.5 year period, since the onset of infection until death with
the cepacia syndrome, revealed that the OAg was only present
in the early isolate but not in any of the late variants (Hassan
et al., 2017). Genomic sequencing of these serial isolates enabled
the identification of mutations, also within the OAg cluster, but
none of these mutations could definitively be associated to OAg
loss (Hassan et al., 2017).
Although the Bcc comprises 24 bacterial species (De Smet
et al., 2015; Depoorter et al., 2016; Ong et al., 2016; Bach et al.,
2017; Weber and King, 2017; Martina et al., 2018) and several
were found to be involved in CF respiratory infections, only B.
cenocepacia (Hassan et al., 2017), B. multivorans (Silva et al.,
2016), and B. dolosa (Lieberman et al., 2011) were examined
concerning the variation of the OAg presence over chronic
infection. B. cenocepacia is recognized as the dominant species
with high potential for inter-patient transmission (Drevinek
and Mahenthiralingam, 2010), and B. multivorans has recently
replaced B. cenocepacia in this first position in several countries
(Lipuma, 2010). However, it is recognized that the less
represented species may also be associated with poor clinical
outcome, but it is not clear why different Bcc species/strains
differ in their ability to persist in the CF lung and in their
pathogenic potential (Woods et al., 2004; Kalish et al., 2006;
Cunha et al., 2007; Moehring et al., 2014; Coutinho et al.,
2015; Nunvar et al., 2016; Marquez et al., 2017; Roux et al.,
2017). It also remains to be elucidated whether LPS OAg loss
confers an advantage to the different Bcc species in particular
and to Gram-negative bacteria, in general, over the course
of infection.
The present study was performed to understand whether OAg
loss in different Bcc species during respiratory infection in CF
patients can be considered a general phenomenon that affects
immune evasion favoring chronic infection. For this, a systematic
retrospective and longitudinal screening was performed based
on a collection of isolates, recovered from 1995 to 2016 from
19 CF patients under surveillance at the major Portuguese CF
treatment center at Hospital de Santa Maria (HSM), in Lisbon,
over the duration of chronic infection (ranging from 1.2 to 15.2
years). The 357 sequential isolates examined were molecularly
identified at the species level and genotyped during this study or
in previous studies and belong to B. cenocepacia, B. multivorans
or to the more rare species in CF population worldwide, B.
dolosa, B. stabilis, B. cepacia and B. contaminans (Cunha et al.,
2003, 2007; Coutinho et al., 2011, 2015; Moreira et al., 2014).
The abnormally high representation of the species B. cepacia
and B. contaminans in our collection is considered related
with a contamination of saline solutions for nasal application
(Cunha et al., 2007; Coutinho et al., 2015). Information on
the health condition of several patients at the time of isolation
based on the forced expiratory values (FEV), an indicator of
pulmonary function and, consequently, of oxygen availability
in the patient’s lung, is also available (Correia et al., 2008;
Moreira et al., 2014). This systematic retrospective study allowed
to answer the question of whether the described variation
of the LPS OAg expression for a limited number of the Bcc
species/strains and patients is extensive to the more rarely found
Bcc species and can be considered a general phenomenon
in the Bcc during long-term respiratory infections in
CF patients.
MATERIALS AND METHODS
Bacterial Isolates and Growth Conditions
The 357 Burkholderia cepacia complex (Bcc) isolates examined
in this study were retrieved from the respiratory secretions
of 19 chronically infected cystic fibrosis (CF) patients under
surveillance at the major Portuguese CF treatment center at
Hospital de Santa Maria (HSM), Centro Hospitalar Lisboa
Norte EPE, Lisbon, from 1995 to 2016, during hospital
routines. The isolates examined in this retrospective study were
selected at random among the colonies isolated in selective
Burkholderia cepacia Selectatab medium at the Hospital, at a
specific date of isolation. Over the years, a significant part
of the isolates were molecularly confirmed to belong to six
Bcc species: Burkholderia cenocepacia, Burkholderia multivorans,
Burkholderia cepacia, Burkholderia contaminans, Burkholderia
dolosa, and Burkholderia stabilis and genotyped (Cunha et al.,
2003, 2007; Coutinho et al., 2011, 2015) (Table 1 and Table S1).
Bacterial cultures are stored at −80◦C in 1:1 (v/v) glycerol.
During this study, bacteria were grown in Lysogeny broth agar
(LB agar; Conda, Pronadisa) at 37◦C with shaking at 250 rpm or
in LB agar plates.
Species Identification and Genotyping of
Bcc Isolates
The isolates examined in this study that had not been
previously identified at the species level and genotyped (by
ribotyping or recA gene PCR Restriction fragment length
polymorphism–recA PCR RFLP–and species-specific recA
direct PCR) were identified and genotyped in this study
based on recA PCR RFLP analysis and Random Amplified
Polymorphic DNA (RAPD) (Mahenthiralingam et al.,
1996, 2000). Genomic DNA was extracted from cells of
those isolates grown overnight in LB broth with orbital
agitation at 37◦C, using the Puregene DNA isolation kit
(cell and tissue kit, Gentra Systems, Qiagen, Germany). The
concentration of the resulting genomic DNA solutions was
estimated using a ND-1000 spectrophotometer (NanoDrop
Technologies). Species identification was based on the recA
PCR RFLP analysis that was performed by amplification









et al., 2000). Bcc recA amplicons were digested with HaeIII
(Amersham Biosciences) and the restriction fragments
separated by electrophoresis in 2% (w/v) agarose gels. The
RFLP patterns obtained were compared with those reported
in the literature (Mahenthiralingam et al., 2000; Vermis
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TABLE 1 | Schematic representation of the sequential isolates from various species chronically infecting the different CF patients examined in this study.
CF patients Number of sequential
isolates with ( ) or





Patient clinical outcome Duration of the chronic
infection with the Bcc
strain (years)
Burkholderia cenocepacia IIIA
I 3 A1 R08/RAPD01 Infection eradicated 2.6
J 1 10 A2 and A3 R11/RAPD02 Dead * 3.4
O 10 A4 R11/RAPD03 Infection eradicated before death 3
P 3 A5 R13/RAPD04 Infection eradicated before death 2.5

















Infection eradicated before death 3.4
0.7
R 12 2 11 B3 and B4 R15/RAPD10 Infection eradicated 7.5
T 6 B5 R16/RAPD11 Infection eradicated before death 1.2
Burkholderia cepacia
D 11 C1 ND/RAPD12 Dead 4.4
N 28 C2 R12 Dead 3.8
O 24 C2 R12 Infection eradicated before death 5.6
AL 10 C1 R19/RAPD12 Infection eradicated 2.2
AP 5 C1 R19 Infection eradicated 2.8










V 13 D1 R17 Alive 15.2
AF 29 D2 R02 Dead 5.8
Burkholderia multivorans
J 2 6 1 E1 and E2 R9 Dead* 4
Burkholderia dolosa


















Information on the number of sequential clonal isolates in which the OAg is present ( ) or absent ( ) and the corresponding OAg profiles (Figure 2), when present, the ripopatterns
of the isolates (Cunha et al., 2003, 2007; Coutinho et al., 2015) and their RAPD profiles (Figure S1) and the duration of the chronic infection and clinical outcome of the infected CF
patients (Cunha et al., 2003, 2007; Coutinho et al., 2011; Moreira et al., 2014) is provided. R, Isolate ribopattern; RAPD, Random amplified polymorphism DNA profile (Figure S1); ND,
not determined; *, cepacia syndrome.
et al., 2002; Cunha et al., 2003; Coutinho et al., 2015). Strain
assignment was performed by RAPD (Mahenthiralingam et al.,





), followed by confirmation










profiles were visually compared by GelJ software (Heras et al.,
2015). Similarity coefficients were calculated using the RAPD
profiles obtained with each primer for the complete set of isolates
examined using Pearson coefficient with Arithmetic Mean
(UPGMA) linkage method.
LPS Extraction and SDS-PAGE Analysis
LPS was extracted from cell envelopes obtained from bacterial
cells as described before (Marolda et al., 1990) with small
modifications (Hassan et al., 2017). Briefly, Bcc cells were
harvested from overnight liquid cultures by centrifugation for
1min after OD640nm adjustment to 2.0 in 1mL of phosphate
buffer saline—PBS (at pH 7.4: 1.8 mM/L KH2PO4, 137 mM/L
NaCl, 2.7 mM/L KCl and 10 mM/L Na2HPO4). These cells were
suspended in 150 µL of lysis buffer, containing 2% SDS, 4% 2-
β-mercaptoethanol, and 500mM Tris-HCl (pH 6.8), and boiled
for 10min. Proteinase K (20 mg/mL) was added, and the samples
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were incubated at 60◦C for 2 h. Finally, samples were mixed
with a tracking dye solution (125mM Tris-HCl [pH 6.8], 2%
SDS, 20% [v/v] glycerol, 0.002% bromophenol blue, and 10%
mercaptoethanol) and boiled for 5min before loading the gels.
LPS samples were resolved by electrophoresis – at 150V for
about 1 h 40 m – in 14% polyacrylamide gels with a Tricine-
SDS system followed by silver staining to visualize the O-antigen
(OAg) banding patterns (Marolda et al., 2006).
Ethics
The present retrospective work involves clinical Bcc isolates
obtained as a part of the hospital routine and its use in clinical
research was approved by the hospital ethics committee. Consent
was obtained from the patient or legal representative for the use
of these isolates in research. Patients’ anonymity is preserved.
RESULTS
During Chronic Infections, B. cenocepacia
recA Lineage IIIA and B. multivorans
Isolates Were More Prone to Lose the OAg
Present in Early Isolates, Compared With
B. cenocepacia recA Lineage IIIB
The 357 Burkholderia cepacia complex (Bcc) isolates tested
in this study were examined with the goal of systematically
compare the O-antigen (OAg) banding patterns when this LPS
component is present and to demonstrate the eventual absence
of the OAg in late isolates (Figure 1 and Table 1). It was found
that the different strains tested and the corresponding clonal
variants obtained during long-term-infection, as demonstrated
byMultilocus sequence typing (MLST), gave rise to characteristic
banding patterns of the OAg whenever this component is present
(Figures 2A,B).
Concerning the 153 isolates of B. cenocepacia recA lineages
IIIA (112 isolates from 7 patients) and IIIB (41 isolates from 3
patients) (Table 1) tested for the presence of OAg polysaccharide
during lung infection (timelines shown in Figure 1), it was found
that strains from B. cenocepacia lineage IIIA were more prone to
lose the OAg than lineage IIIB strains.
There were two cases of extended chronic infection of patients
AB and AN by B. cenocepacia lineage IIIA, with a duration of
14.7 and 6.8 years, respectively (Figure 1A and Table 1), where
the late isolates retrieved after 4.5 or 2.5 years, respectively,
were found to lack the OAg that was present in the early
isolates (Figure 1 and Table S1). The loss of the OAg in late
isolates was also previously reported for another B. cenocepacia
lineage IIIA strain infecting patient J for a shorter period of 3.4
years (Hassan et al., 2017) and (Figure 1 and Table 1). Patient
J was co-infected with a B. multivorans strain and the LPS of
the majority of late isolates of this B. multivorans strain also
lack the OAg present in the early isolates, as shown in the
electrophoretic profiles of the extracted LPS (Figure 2, columns
E1 and E2). However, one B. multivorans clonal isolate retrieved
at the last isolation date exhibited again the OAg, consistent with
the pattern observed before by others (Silva et al., 2016). Late
isolates of B. cenocepacia and B.multivorans were retrieved from
patient J during a period of oxygen depletion in the CF lung that
accompanied disease progression and the deterioration of lung
function. In fact, according to the hospital records, the forced
expiratory values in the first second (FEV1) available are low
during co-infection (22–34%) and no further values of FEV1were
registered during the later stages of the patient’s life due to the
highly severe deterioration of pulmonary function (Figure 1B;
Correia et al., 2008).
Differently, the B. cenocepacia lineage IIIA strain that infected
patient O for 3 year-infection period kept the LPS OAg and the
same was found for the co-infecting Bcc strains of B. cenocepacia
lineage IIIB and B. cepacia chronically infecting patient O for
3.4 and 5.6 years, respectively. Remarkably, the FEV1 values
available were above 50% during the co-infection period and,
after 9 years, the Burkholderia infection was eradicated (Correia
et al., 2008; Figure 1, Table S1). When examining the 11 and
10 B. cenocepacia IIIA isolates obtained from patients’ J and O,
respectively, we were surprised by the fact that the electrophoretic
profiles of the extracted LPS obtained by SDS-PAGE analysis
and silver-staining produced two different profiles (Figure 2,
columns A2 and A4, respectively) even though they were
considered to share the same ribopattern 11 (Table S1; Coutinho
et al., 2011). However, the RAPD analysis of the tested isolates
revealed that they are clonal isolates but from two different
ancestral strains, RAPD02 for patient J and RAPD03 for patient
O (Table 1), in line with the different MLST sequence types, ST-
218 and ST-280 at the MLST database [http://pubmlst.org/bcc/],
obtained for the isolates infecting patient J and O, respectively.
For the B. cenocepacia IIIA strain co-infecting patient AF
for 2.5 years, the loss of the OAg was also observed when
the FEV1 values were close to 40%. However, as demonstrated
by the different RAPD profiles obtained (Table 1), another B.
cenocepacia IIIA strain was obtained at an isolation date after the
loss of the OAg by the original infecting strain; this new strain
exhibit an OAg with a distinct banding pattern from the early
isolates of the series (Figure 2A, column A9), Remarkably, all
the B. contaminans clonal isolates co-infecting this patient kept
the OAg when, for identical isolation times, B. cenocepacia IIIA
clonal isolates lack the OAg (Figure 1B).
Only for B. cenocepacia IIIA isolates chronically infecting
patients I and P over a period of time below 3 years, the loss of
OAg along infection was not observed (Figure 1A). Interestingly,
after this shorter period of chronic infection, the Burkholderia
strains were eradicated from both patients.
Concerning the sequential B. cenocepacia lineage IIIB isolates
retrieved from patient T over 1.2 years of infection before
eradication, all the sequential isolates exhibit the OAg even
though the FEV1 value was in the low range of 25–30%. In the
case of patient R, among the 25 sequential isolates of the B.
cenocepacia lineage IIIB strain obtained during a very extended
infection period (7.5 years) two isolates retrieved after the fifth
year of infection were found to lack the OAg (Figures 1, 2,
columns B3 and B4, and Table 1). Interestingly, the OAg banding
pattern obtained for isolates with ribopattern 15 infecting patient
R was identical to the OAg profile extracted from two isolates
retrieved from patient O (Figure 2, columns B3 and B2) and
identical to those from four B. cenocepacia recA lineage IIIB
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FIGURE 1 | Continued
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FIGURE 1 | Schematic representation of the Bcc isolates examined in this study retrieved from different CF patients over 21 years (from 1995 to 2016) of
epidemiological survey at the CF Center of Hospital de Santa Maria. Time zero marks the date of isolation of the first Bcc isolate from a specific patient with essentially
a single Bcc species/strain (A) or co-infected with different Bcc species (B). The presence or absence of the LPS O-antigen is represented by closed or open
symbols, respectively. The same symbol in a different line is used to indicate a different strain of the same species co-infecting the patient, as detailed in Table 1 and
Table S1, as in the case for patients AU, B, H, O, and AF. Whenever available, the Forced Expiratory Values (%) in the first second (FEV1), before and during infection,
are provided (Correia et al., 2008; Coutinho et al., 2011; Moreira et al., 2014). These values are an indication of the pulmonary function in the infected patients.
* - Sporadic isolation of strains from other Bcc species (in Table S1): B. cenocepacia IIIB - , B. cepacia - , B. multivorans - , and B. dolosa - .
FIGURE 2 | Representative SDS-PAGE gels showing the O-antigen banding patterns obtained (A1–A12, B1–B6, C1–C5, D1, D2, E1, E2, F, G1–G4) for the Bcc
isolates examined. Genotyping data for the different strains tested are also shown: the ribopatterns were obtained before (Cunha et al., 2003, 2007; Coutinho et al.,
2011) and the RAPD profiles were obtained during this study (Figure S1). R, Isolate ribopattern; RAPD, Isolate profile based on Random amplified polymorphism DNA
profiles (Figure S1); ND, not determined. The isolates tested are (Table S1): A1–IST416, A2–IST439, A3–IST4103, A4–IST462, A5–IST432, A6–IST4121,
A7–IST4893, A8–IST4240a, A9–IST4272, A10–IST4253a, A11–IST4197, A12–IST4386, B1–IST435, B2–IST4177, B3–IST438, B4–IST4155, B5–IST466,
B6–IST4481 IIIB, C1–IST4152, C2–IST4128, C3–IST4283, C4–IST4546, C5–IST4198, D1–IST481, D2–IST4193, E1–IST419, E2–IST453, F–IST4208, G1–IST402,
G2–IST409, G3–IST413, G4–IST412.
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isolates also present in patient AR who was mainly infected
with B. dolosa (Figure 2, columns B3 and B6). All these isolates
producing the same banding pattern were confirmed to share
the same RAPD profile (Table 1 and Figure S1). Consistent with
these results the MLST database showed that the B. cenocepacia
lineage IIIB isolates retrieved from patients R and AR also have
the same MLST sequence type (ST-43) [http://pubmlst.org/bcc/].
The OAg Is Stably Expressed in B. cepacia,
B. contaminans and B. stabilis
Regarding the usually less frequent species worldwide that were
examined in this study, the B. cepacia isolates (a total of 87)
retrieved from five patients (N, AL, AP, AQ an AU) infected with
this species for a period of time ranging from 2.2 to 9.6 years, all
exhibit the OAg even when the FEV1 value was as low as 30%
(patient N). Patients AL, AP and AQ, eradicated the infection
after the screening period. Interestingly, the OAg banding pattern
obtained for isolates with ribopattern 19 that infected patients
AL and AP was identical to the OAg profile extracted from
isolates retrieved from patients AU and D (Figure 2, columns
C1 and C3), the sole exception were the two isolates retrieved
from patient AU during the third year of infection with a
different RAPD profile (Figures 1, 2, columns C3 and C4, and
Table 1). All these isolates producing the same banding pattern
were confirmed to share the same RAPD profile (Table 1 and
Figure S1).
Concerning the 13 B. contaminans clonal isolates retrieved
from patient V infected for a very long period of 15.2 years
(Cunha et al., 2003; Coutinho et al., 2011), all of them were found
to express the OAg (Figure 2, column D1).
Regarding the 17 B. stabilis isolates retrieved from patients
B and H for a period of 3.8 and 2.5 years of chronic infection,
respectively (Figure 1 and Table 1), the two strains isolated
from each patient exhibit the same RAPD profiles (Figure S1,
RAPD14 and RAPD15, Table 1). Remarkably, a stable phenotype
concerning the presence or absence of the OAg over the infection
period was found. The four isolates with RAPD15 profile
retrieved from patient B exhibit an LPS that lack the OAg,
independently of being early or late isolates, while the 4 clonal
isolates of the strain with the same RAPD profile obtained from
patient H, all have the OAg (Table 1 and Figure 2, columns
G1 and G4). Interestingly, patient H died from the cepacia
syndrome while patient B death was not related with the cepacia
syndrome. Isolates with RAPD14 profile do have an LPS that
stably maintained the OAg. When present, the banding patterns
of the OAg were different for the two strains but identical for
the clonal variants of each strain obtained from both patients
(Figure 2, columns G2-G4).
The LPS From Early and Late B. dolosa
Isolates Lack the OAg
The analysis of 14 B. dolosa isolates obtained from a single patient
(AR) chronically infected with this species for 5.5 years showed
that this strain did not have an LPS with the OAg chain from
the beginning of the infection until dead (Figure 2F). The very
peculiar B. dolosa LPS chemical structure of the first isolate
IST4208 obtained from patient AR (Table S1) was examined
before and a novel complete structure of the lipooligosaccharide
(LOS) lacking the OAg component was revealed (Lorenzo et al.,
2013). This LOS was found to show a strong proinflammatory
activity (Lorenzo et al., 2013).
DISCUSSION
Different virulence factors have been described in Burkholderia
cepacia complex (Bcc) bacteria (Loutet and Valvano, 2010; Sousa
et al., 2017) but less is known concerning their adaptive traits
during chronic infection, compared with P. aeruginosa, the most
prevalent and studied CF pathogen (Valentini et al., 2018). Before
the systematic retrospective-longitudinal-screening, carried out
in the present study, a retrospective phenotypic longitudinal
assessment of the variation of mucoid exopolysaccharide
production (Zlosnik et al., 2008), the switch from mucoid to
non-mucoid (Zlosnik et al., 2011) and the swimming motility
(Zlosnik et al., 2014) was performed during chronic infections
involving numerous Bcc isolates representing different Bcc
species and collected from 100 CF patients in the Vancouver area.
Conversion of the mucoid-to-non-mucoid phenotype during
chronic infection strengthen the concept of the association of
the non-mucoid phenotype with the severity of the disease
and the mucoid phenotype with persistence (Zlosnik et al.,
2008, 2011). This behavior is in contrast with the phenotypic
switch from non-mucoid to mucoid in P. aeruginosa chronic
infections as a well-established paradigm for infection disease
severity and persistence in this species (Valentini et al., 2018).
Moreover, upon establishment of chronic infection, subsequent
P. aeruginosa isolates show a reduction in the swimming ability
to be non-motile (Valentini et al., 2018), contrasting with the
observed data in Bcc infections (Zlosnik et al., 2014). The
understanding of the occurrence of these and other adaptive
traits that have been well-described in P. aeruginosa chronic
infections (Valentini et al., 2018), but are far less known in Bcc
chronic infection, is instrumental for a better understanding
of bacterial transformations in the CF lungs during long term
infections and infection control.
The LPS forms the outer leaflet of the outermembrane and has
roles in antigenicity, the inflammatory response and exclusion
of external molecules (King et al., 2009). Although the lipid
A can vary, the variability in the O-antigen (OAg) is greater
influencing adherence, colonization and the ability to evade the
host’s defensemechanisms (Kintz and Goldberg, 2008; King et al.,
2009; Saldias et al., 2009; Kotrange et al., 2011; Maldonado et al.,
2016; Ranf, 2016; Kintz et al., 2017). The ability of Bcc species to
evade the host immune response often leads to chronic infections
that are associated with significant loss of lung function due to
the hyperactive inflammatory response that ultimately can lead
to fatalities. The systematic, comprehensive and retrospective
longitudinal screening conducted in this work, covering multiple
sequential isolates from different Bcc strains of species, frequently
or rarely isolated from CF patients, to search for the eventual
lack of OAg expression in the late-stage of infections, reinforce
the relevance that has been attributed to this switch. This was
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particularly frequent and clear for B. cenocepacia recA lineage
IIIA and B. multivorans, also occurring at lower frequency in
B. cenocepacia recA lineage IIIB. However, in the case of B.
multivorans, there is a late isolate obtained within the series
of sequential cloned isolates lacking the OAg that was found
to express it. This behavior was previously observed for B.
multivorans by others (Silva et al., 2016).
For the first time, it was shown that B. cepacia and B.
contaminans do not lose the OAg even during long term
infections that last for periods of time as extended as 9.6 and
15.2 years, respectively. Among the less frequent species, B.
contaminans is currently considered an emerging CF pathogen
(Vanlaere et al., 2009; Martina et al., 2013; Coutinho et al., 2015;
Medina-Pascual et al., 2015; Nunvar et al., 2016; Power et al.,
2016). Concerning the other two rarely found species examined,
B. stabilis exhibits in two infected patients a stable phenotype
concerning the presence or absence of the OAg over the infection
period, consistent with the description of B. stabilis sp. Nov,
as having a relatively stable genome (Vandamme et al., 2000).
For the single patient chronically infected for 5.5 years with the
more distantly related Bcc species B. dolosa, the OAg chain was
absent from the beginning of the infection until the patient death.
The novel LPS structure of this B. dolosa strain was examined
and its strong pro-inflammatory activity reported before
(Lorenzo et al., 2013).
The conclusions from this work were in general supported
by the results gathered and suggest that the observed switch
frequency of the OAg expression appears to be species dependent
and also dependent on the duration of the infection and the
level of deterioration of the lung function, increasing with
both. This observation is consistent with the fact that cystic
fibrosis is a genetic disorder associated with inflammation,
sub-optimal antioxidant protection and the continuous use of
antimicrobial therapy, all resulting in marked oxidative stress
(Galli et al., 2012) that causes an increase in mutation rate.
Results obtained from co-infected patients with different Bcc
species reinforce those conclusions as it is for example the
case for patient AF who was infected with B. contaminans
isolates that kept the OAg during 5.8 years of chronic
infection while late clonal isolates of the co-infecting B.
cenocepacia IIIA strain during a much shorter period of 2.5 loss
the OAg.
It is interesting to note that the two Bcc species that
showed a higher tendency to lose the OAg expression
along chronic lung infections in CF (B. cenocepacia and B.
multivorans) are also the two most prevalent worldwide and
the most feared among the CF community (Jones et al., 2004;
Mahenthiralingam et al., 2005). Remarkably, B. cenocepacia
and B. multivorans cell lysates are more potent stimulators of
pro-inflammatory cytokines compared with those from other
Bcc species (De Soyza et al., 2004). However, even though
the prevalence of B. multivorans has recently replaced B.
cenocepacia in several countries (Baldwin et al., 2008; Lipuma,
2010; Medina-Pascual et al., 2012; Peeters et al., 2017), it
is clear that B. cenocepacia recA lineage IIIA remains the
most dominant species (Manno et al., 2004; Nunvar et al.,
2017; Scoffone et al., 2017; Teri et al., 2018). Remarkably,
the particularly destructive nature of B. cenocepacia recA
group IIIA infections in CF patients when compared with
other Bcc bacteria has been reported (Manno et al., 2004;
Zlosnik et al., 2015).
Remarkably, the single clone of the more distantly related B.
dolosa Bcc species tested did not exhibit the OAg chain from
the beginning to the end of the 5.5 year-infection as reported
before (Lorenzo et al., 2013). Comprehensive comparative
genomic studies performed during chronic infection on the
most feared B. cenocepacia (Nunvar et al., 2017) and B.
multivorans (Silva et al., 2016) and on the far less distributed
B. dolosa (Lieberman et al., 2011); revealed that the genes
affected during adaptive evolution in B. cenocepacia or in
B. multivorans are different from B. dolosa. This indicates
that evolution in B. dolosa during chronic CF infection is
driven by different selective forces presumably linked to host
immune responses (Lieberman et al., 2014; Nunvar et al.,
2017). Specifically, while the most mutated genes reported to
undergo adaptive within-patient evolution in B. cenocepacia
were associated with oxidative stress response and transition
metal metabolism, the same was not observed either in B.
dolosa or in Pseudomonas aeruginosa (Lieberman et al., 2014;
Nunvar et al., 2017). These genes encode proteins required for
protection against the reactive oxygen species (ROS) produced
by leukocytes thus suggesting the involvement of the host
immune system in driving B. cenocepacia evolution during
chronic CF infection (Nunvar et al., 2017). Given that persistent
inflammation and neutrophil infiltration often accompany
chronic lung infections, the authors hypothesized that under
increased stress encountered in CF macrophages, the global
stress response might be activated by the evolved bacterial
population and thus modulate the course of infection (Chua
et al., 2016, 2017; Nunvar et al., 2017). Since the interactions
between pathogens and the immune system are highly complex,
affecting pathogen adaptation to different host immune system
stimuli, further investigation into the roles of macrophages and
defense mechanisms in chronic infection outcome is needed
(Chua et al., 2016, 2017).
The presence/absence of the OAg at the Bcc bacteria surface
is important for cell evasion from the host immune response
and pathogenicity. The OAg is considered highly immunogenic
and induces the production of antibodies that may activate the
complement pathway, either through the classic pathway or an
alternate pathway, which leads to cellular death or phagocytosis
(Reyes et al., 2012). Certain modifications in the oligosaccharide
chain of the OAg may alter the interaction of the complement
pathway. Several OAg of pathogens are similar to host molecules
and this facilitate invasion through mimicking in the host
(Reyes et al., 2012). An OAg deficient B. cenocepacia strain
was found to be more susceptible to phagocytic internalization
(Saldias et al., 2009) while, the loss of OAg expression in P.
aeruginosa during chronic pulmonary infection did not confer
phagocytic resistance in vitro (Demirdjian et al., 2017). Given
that Burkholderia is a non-obligate intracellular pathogen while
P. aeruginosa is considered an extracellular pathogen, it was
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hypothesized that the loss of OAg may benefit the ability of
Burkholderia to access an intracellular environment, having
no similar benefits for P. aeruginosa (Saldias et al., 2009).
Recent studies suggest that there is a high selective pressure
on the OAg biosynthetic locus leading to alterations both at
the structural, genetic and regulatory levels strongly suggestive
of an adaptive mechanism that potentially contribute to evade
the host immune defenses in several Gram-negative pathogens
(Murray et al., 2003; Yang et al., 2011; Maldonado et al.,
2016; McCarthy et al., 2017; Faure et al., 2018; Neiger et al.,
2019). Moreover, the OAg absence was shown to increase Bcc
survival in eukaryotic cells as amoebae, epithelial cells and
human macrophages (Saldias and Valvano, 2009; Saldias et al.,
2009; Kotrange et al., 2011; Maldonado et al., 2016), leading
to increased internalization of B. cenocepacia into macrophages
upon phagocytosis (Saldias et al., 2009; Kotrange et al., 2011) and
to facilitate B. multivorans growth inside macrophage (Schmerk
and Valvano, 2013). These results may suggest that OAg loss
could promote Bcc persistence through intracellular survival.
Remarkably, the comparison of the ability to subvert the host’s
immune function, assessed by internalization assays using human
dendritic cells, of three of the B. cenocepacia isolates examined
in this work and retrieved from CF patient J showed that the
late variants, IST4113 and IST4134, were significantly more
internalized exhibiting increased survival within dendritic cells
than the early isolate IST439 (Cabral et al., 2017). This early
isolate was the only one that expresses the OAg unit (Hassan
et al., 2017) supporting the idea that the loss of the OAg is
advantageous for Bcc persistence. In addition, the absence of the
OAg in these same isolates was suggested to reduce B. cenocepacia
virulence potential using the Galleria mellonella infection model
(Moreira et al., 2017). Such decrease in the virulence potential
of early B. cenocepacia clonal variants exhibiting the OAg
compared with late clonal variants lacking the OAg was also
observed for two other chronically infected patients (AB and AN)
with B. cenocepacia (Moreira et al., 2017). Also, a Salmonella
typhimurium mutant missing the entire OAg was found to be
avirulent inG. mellonella infection model while the shortening of
the OAg chain length reduced the pathogenic potential by one-
half compared to wild-type strain (Bender et al., 2013) suggesting
that the OAg length is also a key-determinants of virulence
in G. mellonella. The OAg truncation has also been implicated
in increased neutrophil-mediated killing, complement-mediated
susceptibility and phagocytosis of Salmonella by macrophages
(Murray et al., 2003).
It is essential to obtain comprehensive knowledge about
the pathogenesis of the various Bcc species involved in acute
or chronic infections in different patients in order to fight
the associated infections. This work reinforces the relevance
that has been attributed to the switch involved in the lack of
expression of the OAg during chronic infection in the most
feared pathogenic Bcc species B. cenocepacia (in particular
the recA lineage IIIA) and B. multivorans. It also suggests
that the evolution of different Bcc species in chronic CF
infection also at the level of OAg expression may be driven
by different selective forces presumably associated to host
immune responses.
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Figure S1 | Representative profiles based on Random Amplified Polymorphic
DNA (RAPD) analysis of the Bcc isolates examined in this study retrieved from
different CF patients during several years of chronic infection. The polymorphisms
shown are based on the amplification by RAPD primers 270 (A), 208 (B), and 272
(C) in the same sequential order. The polymorphisms originated were analyzed
using the software GelJ to detect the banding patterns. These profiles correspond
to the 15-different representative selected isolates of B. cenocepacia IIIA (RAPD
01-08), B. cenocepacia IIIB (RAPD 09-11), B. cepacia (RAPD 12 and 13), and B.
stabilis (RAPD 14 and 15). RAPD profiles for isolates: 01–IST416, 02–IST439,
03–IST462, 04–IST432, 05–IST4121, 06–IST4240a, 07–IST4272, 08–IST4197,
09–IST435, 10–IST438, 11–IST466, 12–IST4152, 13–IST4546, 14–IST413,
15–IST412 and λ−1Kb plus DNA ladder.
Table S1 | Detailed description of the Burkholderia sequential isolates per patient
examined in this study with their isolation dates. The presence or absence of the
LPS OAg is presented by + or – symbols, respectively, and their corresponding
profiles (Figure 2) is provided. Information on the species identification and
genotyping for the different strains tested are also presented: the genotyping data
and the ribopatterns were obtained before (Cunha et al., 2003, 2007; Coutinho
et al., 2011, 2015; Moreira et al., 2014, 2017) and the RAPD profiles were
obtained in this study (Figure S1) together with the sequence type, when present
in the MLST database. The different letter (A, B, C and D) of the isolate signature
(as ISTnumber A, B, C or D) was used to indicate different clone at the same
isolation date. ND, Not determined.
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